Company Focus
Lonza
Latest Lonza News
Pharmaceutical
A fresh attempt to bring more pharmaceutical manufacturing back to US soil has put the sector on alert, as a new executive order from Donald Trump seeks to overhaul how American medicines are made and regulated. But a research note from GlobalData suggests the move could raise as many questions as it tries to answer. 10 June 2025
Cell & Gene Therapy News
Insights
Company Spotlight
A biopharma company utilising small interfering RNAs (siRNAs) to improve and expand the reach of RNAi-based medicines.
Latest News & Features of interest to Lonza
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Pharmaceutical
A fresh attempt to bring more pharmaceutical manufacturing back to US soil has put the sector on alert, as a new executive order from Donald Trump seeks to overhaul how American medicines are made and regulated. But a research note from GlobalData suggests the move could raise as many questions as it tries to answer. 10 June 2025
Biotechnology
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
Biotechnology
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
Biotechnology
US gene therapy company RegeNXBio yesterday announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202, RegeNXBio’s potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. 6 June 2025
Biotechnology
German genetic medicine company ViGeneron has announced a rebrand to become VeonGen Therapeutics. 5 June 2025
Biotechnology
US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ahead with its cardiac gene therapy pipeline and fund operations into 2028. 28 May 2025
Biotechnology
German biotech TQ Therapeutics today announced the acquisition of Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Financial terms of the agreement were not disclosed. 28 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Latest In Brief for Lonza
Biotechnology
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. 8 February 2025
Latest Cell & Gene Therapy Ones To Watch News
German biotech TQ Therapeutics today announced the acquisition of Juno Therapeutics GmbH, a cell therapy company, through a share purchase agreement. Financial terms of the agreement were not disclosed. 28 May 2025
17 April 2025
29 March 2025
Cell & Gene Therapy Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze